The DOI matches its Crossref record; 209 of the 211 references it cites were found in a registry or an index.
Synaptic dysfunction and altered excitability in C9ORF72 ALS/FTD
Open accessAbstract
Amyotrophic lateral sclerosis (ALS) is characterized by a progressive degeneration of upper and lower motor neurons, resulting in fatal paralysis due to denervation of the muscle. Due to genetic, pathological and symptomatic overlap, ALS is now considered a spectrum disease together with frontotemporal dementia (FTD), the second most common cause of dementia in individuals under the age of 65. Interestingly, in both diseases, there is a large prevalence of RNA binding proteins (RBPs) that are mutated and considered disease-causing, or whose dysfunction contribute to disease pathogenesis. The most common shared genetic mutation in ALS/FTD is a hexanucleuotide repeat expansion within intron 1 of C9ORF72 (C9). Three potentially overlapping, putative toxic mechanisms have been proposed: loss of function due to haploinsufficient expression of the C9ORF72 mRNA, gain of function of the repeat RNA aggregates, or RNA foci, and repeat-associated non-ATG-initiated translation (RAN) of the repeat RNA into toxic dipeptide repeats (DPRs). Regardless of the causative mechanism, disease symptoms are ultimately caused by a failure of neurotransmission in three regions: the brain, the spinal cord, and the neuromuscular junction. Here, we review C9 ALS/FTD-associated synaptic dysfunction and aberrant neuronal excitability in these three key regions, focusing on changes in morphology and synapse formation, excitability, and excitotoxicity in patients, animal models, and in vitro models. We compare these deficits to those seen in other forms of ALS and FTD in search of shared pathways, and discuss the potential targeting of synaptic dysfunctions for therapeutic intervention in ALS and FTD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The combination of NPTX2 (representing synaptic plasticity [35]), NfL (marker for overall neurodegeneration [60, 61]), and GFAP (depicting astrogliosis [62]) reflects the complexity of pathological mechanisms involved in neurodegenerative disorders and FTD in particular [63–66]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Dukkipati, S. S., Chihi, A., Wang, Y., & Elbasiouny, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0281-16.2016 · Cited by 23
Antonini, A., Caioli, S., Saba, L., Vindigni, G., Biocca, S., Canu, N., & Zona, C. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.11.008 · Cited by 22
Brettle, M., Suchowerska, A. K., Chua, S. W., Ittner, L. M., & Fath, T. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.09.034 · Cited by 16
Radzicki, D., Liu, E., Deng, H., Siddique, T., & Martina, M. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00216 · Cited by 15
Cortical Hyperexcitability in Amyotrophic Lateral Sclerosis
Wainger, B. J., & Cudkowicz, M. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.2197 · Cited by 14
Danbolt, N. C., Storm‐Mathisen, J., & Ottersen, O. P. (1994) · Progress in brain research · doi:10.1016/s0079-6123(08)60768-2 · Cited by 13
Cortical excitability differences between flexor pollicis longus and APB
Bae, J. S., Menon, P., Mioshi, E., Kiernan, M. C., & Vucic, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.03.003 · Cited by 13
Zhang, Y., Ni, W., Horwich, A. L., & Kaczmarek, L. K. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.3102-16.2017 · Cited by 9
Flagged first, then by citations
2 of the 211 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Geevasinga, 2015, Cortical function in asymptomatic carriers and patients With C9orf72 amyotrophic lateral sclerosis, JAMA Neurol., 1
Cited by
Sorted by citations
Hallmarks of neurodegenerative diseases
Wilson, D. M., Cookson, M. R., Van Den Bosch, L., Zetterberg, H., Holtzman, D. M., & Dewachter, I. (2023) · Cell · doi:10.1016/j.cell.2022.12.032 · Cited by 1,789
C9ORF72: What It Is, What It Does, and Why It Matters
Smeyers, J., Banchi, E.-G., & Latouche, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661447 · Cited by 198
Repeat‐associated non‐AUG translation in C9orf72‐ALS/FTD is driven by neuronal excitation and stress
Westergard, T., McAvoy, K., Russell, K. A., Wen, X., Pang, Y., Verdone, B. M., Pasinelli, P., Trotti, D., & Haeusler, A. R. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809423 · Cited by 126
Liu, W., Venugopal, S., Majid, S., Ahn, I. S., Diamante, G., Hong, J. S., Yang, X., & Chandler, S. H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104877 · Cited by 88
Abnormal Mitochondrial Quality Control in Neurodegenerative Diseases
Yan, X., Wang, B., Hu, Y., Wang, S., & Zhang, X. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00138 · Cited by 74
Metadata
- Authors
- Starr, A., & Sattler, R.
- Affiliations
- Barrow Neurological Institute (US)
- Corresponding author
- Sattler, Rita
- Venue
- Brain Research
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 1693
- Issue
- Pt A
- Pages
- 98-108
- ISSN
- 0006-8993 (ISSN-L)
- PMC
- PMC5997509
- OpenAlex
- W2790884408
- Cited by
- 78
- References
- 211
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 7 · 2022: 21 · 2021: 15 · 2020: 10 · 2019: 5 · 2018: 3
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Fogarty International Center
- National Institute of Neurological Disorders and Stroke (R01NS085207)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- C9orf72, amyotrophic lateral sclerosis, frontotemporal dementia, synaptic dysfunction, neuronal excitability, excitotoxicity, RNA-binding proteins, hexanucleotide repeat expansion, dipeptide repeat proteins, repeat-associated non-ATG translation, RNA foci, neuromuscular junction, synaptogenesis, motor neurons, therapeutic target
- MeSH terms
- C9orf72 Protein, Amyotrophic Lateral Sclerosis, Animals, Humans, Motor Neurons, Mutation, RNA, Synapses, RNA-Binding Proteins, Frontotemporal Dementia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
